GHRP-2 vs GHRP-6: First-Generation GHRP Comparison | Regena

GHRP-2 is a hexapeptide ghrelin-receptor agonist engineered for potent growth-hormone release, with a smaller appetite-axis effect than GHRP-6 but measurable cortisol and prolactin activity at research doses.

GHRP-6 is a hexapeptide ghrelin-receptor agonist engineered for growth-hormone release with a distinctive strong appetite-axis effect — the reference research tool for ghrelin-axis appetite-stimulation studies. It also produces cortisol and prolactin activity at research doses.

Both compounds act at the GHS-R1a receptor. GHRP-2 has stronger GH-release potency per dose than GHRP-6, while GHRP-6 has the stronger appetite-axis signal — the two off-target profiles are the practical differentiators in research design.

Both compounds are less selective than ipamorelin, which is why modern growth-hormone-axis research protocols favour ipamorelin as the standard GHRP arm unless the older-generation pharmacology is specifically part of the experimental design.

Both compounds have short native pharmacokinetic half-lives and are used at once- to three-times-daily research cadences in published preclinical protocols.

The similar pharmacokinetic profiles make direct GHRP-2 vs GHRP-6 comparator studies clean — the differences that emerge are receptor-selectivity and off-target-profile differences rather than cadence artefacts.

GHRP-2 is used in growth-hormone-axis research where a potent first-generation GHRP arm is needed without the strong appetite-axis signal of GHRP-6.

GHRP-6 is the standard research tool for ghrelin-axis appetite-stimulation studies, and is used in growth-hormone-axis research where the appetite-axis effect is either part of the design or an acceptable off-target.

Both GHRP-2 and GHRP-6 ship from Regena only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both GHRP-2 and GHRP-6 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose GHRP-2 when the protocol requires a potent first-generation GHRP arm without the appetite-axis confound. Researchers choose GHRP-6 when appetite-axis stimulation is central to the experimental design, or when comparator studies need both first-generation GHRPs in matched arms alongside a modern selective GHRP such as ipamorelin.

For multi-compound comparator studies, the Regena consultations team will reserve matched-batch inventory of both GHRP-2 and GHRP-6 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both GHRP-2 and GHRP-6 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.